DE69526120T2 - Verwendung von nebivolol als anti-atherogenisches mittel - Google Patents

Verwendung von nebivolol als anti-atherogenisches mittel

Info

Publication number
DE69526120T2
DE69526120T2 DE69526120T DE69526120T DE69526120T2 DE 69526120 T2 DE69526120 T2 DE 69526120T2 DE 69526120 T DE69526120 T DE 69526120T DE 69526120 T DE69526120 T DE 69526120T DE 69526120 T2 DE69526120 T2 DE 69526120T2
Authority
DE
Germany
Prior art keywords
nebivolol
alpha
atherogenic agent
atherogenic
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69526120T
Other languages
English (en)
Other versions
DE69526120D1 (de
Inventor
Chaffoy De Courcelles Didie De
Simone Lesage
Eduarda Leysen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of DE69526120D1 publication Critical patent/DE69526120D1/de
Application granted granted Critical
Publication of DE69526120T2 publication Critical patent/DE69526120T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
DE69526120T 1994-12-28 1995-12-21 Verwendung von nebivolol als anti-atherogenisches mittel Expired - Lifetime DE69526120T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94203775 1994-12-28
PCT/EP1995/005174 WO1996019987A1 (en) 1994-12-28 1995-12-21 Use of nebivolol as an anti-atherogenic

Publications (2)

Publication Number Publication Date
DE69526120D1 DE69526120D1 (de) 2002-05-02
DE69526120T2 true DE69526120T2 (de) 2002-11-28

Family

ID=8217503

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69526120T Expired - Lifetime DE69526120T2 (de) 1994-12-28 1995-12-21 Verwendung von nebivolol als anti-atherogenisches mittel

Country Status (20)

Country Link
US (2) US5874461A (de)
EP (1) EP0801564B1 (de)
JP (1) JPH10511655A (de)
KR (1) KR100264348B1 (de)
CN (1) CN1167418C (de)
AT (1) ATE214924T1 (de)
AU (1) AU700364B2 (de)
CA (1) CA2207333C (de)
CZ (1) CZ287513B6 (de)
DE (1) DE69526120T2 (de)
DK (1) DK0801564T3 (de)
ES (1) ES2176354T3 (de)
FI (1) FI118884B (de)
HU (1) HU226208B1 (de)
NO (1) NO315687B1 (de)
NZ (1) NZ298074A (de)
PT (1) PT801564E (de)
SI (1) SI0801564T1 (de)
SK (1) SK282144B6 (de)
WO (1) WO1996019987A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0801564T1 (en) * 1994-12-28 2002-08-31 Janssen Pharmaceutica N.V. Use of nebivolol as an anti-atherogenic
DE19716120A1 (de) * 1997-04-17 1998-10-22 Europ Lab Molekularbiolog Verwendung von cholesterinsenkenden Mitteln
US6713651B1 (en) 1999-06-07 2004-03-30 Theravance, Inc. β2-adrenergic receptor agonists
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
JP2000207219A (ja) * 1999-01-18 2000-07-28 Fujitsu Ten Ltd 車載端末とセンタ―との間の通信システム、及び、通信システムに使用する車載端末
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
US6593497B1 (en) 1999-06-02 2003-07-15 Theravance, Inc. β2-adrenergic receptor agonists
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
AU2002338528B2 (en) * 2001-05-02 2008-01-24 Nicox S.A. Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
EP1558922B1 (de) * 2002-10-30 2013-02-27 Ampere Life Sciences, Inc. Identifizieren therapeutischer verbindungen auf grundlage ihrer physikalisch-chemischen eigenschaften
ITTO20030140U1 (it) * 2003-09-16 2005-03-17 Interfila Srl Matita cosmetica
WO2005032544A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Treatment of mitochondrial diseases
US7803838B2 (en) 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
EP1737847B1 (de) 2004-07-30 2008-06-04 Torrent Pharmaceuticals Ltd Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
EP1848424B1 (de) * 2005-01-31 2017-04-05 Mylan Laboratories, Inc Pharmazeutische zusammensetzung enthaltend hydroxyliertes nebivolol
EP2471530B1 (de) 2005-06-01 2017-01-11 Edison Pharmaceuticals, Inc. Redoxaktive therapeutik zur behandlung von mitochondrialen erkrankungen und anderen zuständen sowie modulation von energie-biomarkern
CA2635280C (en) 2006-02-22 2017-12-12 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
WO2009061744A2 (en) 2007-11-06 2009-05-14 Edison Pharmaceuticals, Inc. 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
US20090181975A1 (en) * 2008-01-15 2009-07-16 Forest Laboratories Holdings Limited Nebivolol in the treatment of sexual dysfunction
EP2262508B1 (de) 2008-03-05 2018-10-03 BioElectron Technology Corporation SUBSTITUIERTE p-CHINONDERIVATE ZUR BEHANDLUNG VON ERKRANKUNGEN IN VERBINDUNG MIT OXIDATIVEM STRESS
WO2010030607A1 (en) 2008-09-10 2010-03-18 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
US10039722B2 (en) 2008-10-14 2018-08-07 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
JP5719309B2 (ja) * 2008-12-19 2015-05-13 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 哺乳動物細胞培養用の栄養補助剤及び使用方法
DK2424495T3 (en) 2009-04-28 2018-04-30 Bioelectron Tech Corp TREATMENT OF LEVERS HEREDIC OPTICAL NEUROPATHY AND DOMINANT OPTICAL ATROPHY WITH TOCOTRIENOL QUINONES
WO2011150859A1 (en) * 2010-06-04 2011-12-08 Comprehensive Drug Enterprises Ltd Oral meclizine aqueous formulations with taste flavoring agent
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
DE102014107132A1 (de) 2014-05-20 2015-11-26 Corden Pharma International Gmbh Verfahren zur Herstellung von Epoxiden die in der Herstellung von Nebivolol und dessen Derivaten einsetzbar sind
TW201615191A (zh) * 2014-10-24 2016-05-01 朗齊生物醫學股份有限公司 氨氯地平藥物應用於癌症治療
KR102626895B1 (ko) 2014-12-16 2024-01-18 피티씨 테라퓨틱스, 인크. (r)-2-하이드록시-2-메틸-4-(2,4,5-트리메틸-3,6-디옥소사이클로헥사-1,4-디에닐)부탄아미드의 다형성 및 무정형 형태
WO2017106803A1 (en) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1337432C (en) * 1988-03-23 1995-10-24 Raymond M. Xhonneux Method of lowering the blood pressure
TW355683B (en) * 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
SI0801564T1 (en) * 1994-12-28 2002-08-31 Janssen Pharmaceutica N.V. Use of nebivolol as an anti-atherogenic

Also Published As

Publication number Publication date
NO972980D0 (no) 1997-06-26
EP0801564B1 (de) 2002-03-27
WO1996019987A1 (en) 1996-07-04
ES2176354T3 (es) 2002-12-01
HU226208B1 (en) 2008-06-30
SI0801564T1 (en) 2002-08-31
NO972980L (no) 1997-06-26
AU4347796A (en) 1996-07-19
DK0801564T3 (da) 2002-07-15
MX9704669A (es) 1997-09-30
PT801564E (pt) 2002-09-30
US6075046A (en) 2000-06-13
CA2207333C (en) 2006-10-17
SK282144B6 (sk) 2001-11-06
EP0801564A1 (de) 1997-10-22
CN1171739A (zh) 1998-01-28
CZ287513B6 (en) 2000-12-13
FI972793A (fi) 1997-06-27
CN1167418C (zh) 2004-09-22
KR100264348B1 (ko) 2000-08-16
ATE214924T1 (de) 2002-04-15
AU700364B2 (en) 1999-01-07
DE69526120D1 (de) 2002-05-02
CA2207333A1 (en) 1996-07-04
JPH10511655A (ja) 1998-11-10
US5874461A (en) 1999-02-23
FI118884B (fi) 2008-04-30
FI972793A0 (fi) 1997-06-27
NZ298074A (en) 2001-01-26
CZ191997A3 (cs) 1999-01-13
SK85697A3 (en) 2000-04-10
HUT77927A (hu) 1998-11-30
NO315687B1 (no) 2003-10-13

Similar Documents

Publication Publication Date Title
DE69526120T2 (de) Verwendung von nebivolol als anti-atherogenisches mittel
TR199901174T2 (xx) Yeni heterosiklilmetil-ikameli pirazol t�revleri.
HUP9700603A1 (hu) Gyógyászati készítmény véralvadási zavarok kezelésére
TR199901172T2 (xx) Yeni ikame edilmi� pirazol t�revleri.
DE69920757D1 (de) Immunsuppressive wirkungen von pteridinderivaten
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
ATE239474T1 (de) Verwendung von levobupivacain
ATE252897T1 (de) Verwendung von p-aminophenolderivaten zur herstellung von pharmazeutischen zusammensetzungen zur behandlung von neurodegenerativen erkrankungen
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
BG102707A (en) New triazolopurinpurines, method for their preparation and appplication as medicamentous forms
ATE528279T1 (de) 3-butenyl-1-aminederivate und ihre verwendung als ih modulatoren von therapie für psychiatrische erkrankungen
ATE151774T1 (de) Cyclopentanperhydrophenanthren-17-beta-(3-furyl - 3-derivate und pharmazeutische präparate davon, zur behandlung von kardiovaskulär-erkrankungen
DE69910425D1 (de) Neue therapeutische verwendung von nicergoline
DE59708511D1 (de) Verwendung von 7-(1-aminomethyl-2-oxa-7-aza-bicyclo 3.3.0]oct-7-yl)-chinoloncarbonsäure- und -naphthyridoncarbonsäure-derivaten zur therapie von helicobacter-pylori-infektionen und den damit assoziierten gastroduodenalen erkrankungen
NO984651D0 (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
AU1569700A (en) Novel therapeutic application of low molecular weight heparin
TR200003352T2 (tr) Yeni pentaerythrit türevleri, bunların imalatı ve kullanımları ile bunların sentezi için ara maddeler
TR199901385T2 (xx) Piperidin t�revleri.
ATE225181T1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
NO984198D0 (no) Fremgangsmåte for behandling av aggresjon
AU1278700A (en) Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline
MX9706454A (es) Uso de benzotiazoles fusionados como neuroproyectores.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition